Trial | NCT03668054  Report issue

Title

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)
Clinical Study for Evaluating the Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration.

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    22
The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with wet AMD.
Age-related macular degeneration is the main cause of severe vision loss in patients over 65 years of age. There is solid evidence of the efficacy and safety of bevacizumab in the treatment of wet AMD. However, it has not been registered for such indication yet.

In response to the need for a proper adaptation, Lumiere® has been developed in a single-dose, sterile dosage containing bevacizumab 5 mg/vial in 0.2 mL injectable solution.

This adaptation is intended to assure intravitreal administration avoiding the risk of contamination and potential adverse consequences, such as endophthalmitis and blindness, associated to reutilization or repackaging of bevacizumab vials for oncological use.
Study Started
Feb 07
2017
Primary Completion
May 30
2018
Study Completion
May 30
2018
Last Update
Oct 28
2020

Drug Bevacizumab (Lumiere®)

The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.

Bevacizumab (Lumiere®) Experimental

Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)

Criteria 

Inclusion Criteria:

Patients over 50 years of age diagnosed with wet age-related macular degeneration having indication of antiangiogenic therapy.
Both genders.
Subjects able to give informed consent.

Exclusion Criteria:

Patients with contraindication to receive bevacizumab:

Hypersensitivity to the active ingredient or to some of the formula excipients.
Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies.
Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment.
Patients receiving previous systemic antiangiogenic therapy.
Wet AMD in the healing period or disciform scar.
Pregnant, breastfeeding or childbearing-aged women.
Any person with choroidal neovascularization not associated to wet AMD.
History of retinal or intraocular surgery in the affected eye in the last three months.
Vitrectomy in the affected eye.
Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied.
Ocular inflammatory disease.
Myopia exceeding -8 diopters.
Extensive subfoveal subretinal hemorrhage > 2 papillary diameter (PD).
Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.
History of stroke or myocardial infarction in the last 6 months.
Patients with coagulopathies.
Patients physically or mentally disabled to participate in such visual tests.
No Results Posted